The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Abstract Novel therapies have achieved unprecedented benefit in survival of advanced melanoma patients. While immunotherapy (ICI) can be administered independent of mutational status, BRAF and MEK kinase inhibitors represent another effective treatment option for patients with BRAF mutant melanoma....

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Reinhard Dummer, Michèle Welti, Egle Ramelyte
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2023-08-01
Schriftenreihe:	Journal of Translational Medicine
Schlagworte:	BRAF mutant melanoma Triple Immunotherapy Targeted therapy
Online-Zugang:	https://doi.org/10.1186/s12967-023-04391-1
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!